Using hydromorphone to treat acute chest pain

Intravenous Acetaminophen Versus Intravenous Hydromorphone for the Treatment of Acute Pain: A Single-Center, Prospective, Single-Arm Study

This study tests if hydromorphone can help people with severe chest pain feel better and recover faster.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Ages: 18 Years to 64 Years
• Sex: All
• Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (Academic / other)
• Locations: 1 site (Nanjing, Jiangsu)
• Trial ID: NCT06949059 on ClinicalTrials.gov

What this trial studies

This study aims to evaluate the efficacy and safety of hydromorphone for managing acute chest pain in patients. It focuses on patients who present with severe pain requiring opioid treatment within 24 days of onset. The research will provide insights into the potential benefits of hydromorphone for individualized pain management and rapid recovery. The study will involve monitoring patient responses to the medication and assessing its overall effectiveness.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-64 who are experiencing acute chest pain and require opioid analgesia.

Not a fit: Patients with known allergies to hydromorphone or those with chronic pain conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this could lead to improved pain management strategies for patients experiencing acute chest pain.

How similar studies have performed: Other studies have explored opioid treatments for acute pain, but the specific use of hydromorphone in this context may provide novel insights.

Eligibility criteria

Inclusion criteria:

1. Age 18-64 years old;
2. Gender is not limited;
3. Patients with acute chest pain, with the time from pain onset to visit the doctor ≤ 24 days;
4. Severe pain that requires the use of opioids to control as determined by emergency physicians;
5. Obtain informed consent from the patient or family members.

Exclusion criteria:

1. Known allergy to hydromorphone or morphine;
2. Systolic blood pressure \<100 mmHg, oxygen saturation \<95%, pulse less than 60 beats/min;
3. Use of acetaminophen or nonsteroidal anti-inflammatory drugs in the past 8 hours;
4. Chronic pain, defined as pain lasting for more than 12 weeks;
5. Delirium, alcohol withdrawal symptoms or other drug intoxication;
6. Pregnant or lactating women;
7. Patients with mental or neurological diseases, cognitive and consciousness disorders and inability to express correctly;
8. Participating in any other research at the same time;
9. Factors that increase the risk of participating in the study (life-threatening chest pain patients who require rapid diagnosis or treatment intervention, such as resuscitation status, excluding chest pain caused by myocardial infarction), who are judged by the researchers to be unsuitable for inclusion in the study.

Where this trial is running

Nanjing, Jiangsu

• Nanjing Drum Tower Hospital — Nanjing, Jiangsu, China (Recruiting)

Study contacts

• Study coordinator: Hao Sun, MD, PhD

Conditions Acute Chest Pain